Graham Walmsley is an Investment Professional at Versant Ventures focused on the creation and development of biotechnology and healthcare companies. Since joining Versant in 2016, Graham helped build and launch BlueRock Therapeutics, a regenerative medicine company formed in partnership with Bayer through one of the largest Series A investments in biotech history. Graham has been actively involved in several other Versant portfolio companies including Jecure Therapeutics, a first-in-class NASH and fibrosis company, where he currently leads business development.
Graham holds a Ph.D. from Stanford University and a B.A. in Molecular Biology with summa cum laude honors from the University of California, Berkeley.